PUBLISHED

N.C.G.S. § 90-325.32

No liability to heirs for outstanding debt related to use of individualized investigational drugs, biological products, or devices.

Effective date: 2026-08-08
Last verified: 2026-08-09
Source: official source
Revision history: view all versions

Download PDF

If an eligible patient dies while being treated with an individualized investigational drug, biological product, or device, the eligible patient's heirs are not liable for any outstanding debt related to the treatment, including any costs attributed to lack of insurance coverage for the treatment. (2024-36, s. 1.)